Pancreatic cancer in mice and man: The Penn Workshop 2004

Cancer Research

Volumn 66, Issue 1, 2006, Pages 14-17

  Hruban, Ralph H ^a   Rustgi, Anil K ^b   Brentnall, Teresa A ^c   Tempero, Margaret A ^d   Wright, Christopher V ^e   Tuveson, David A ^b,f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEMCITABINE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN PANIN 1A; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ANIMAL MODEL; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SCREENING; CANCER SURGERY; CARCINOMA IN SITU; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUING EDUCATION; DRUG EFFICACY; EDUCATION PROGRAM; GENE TARGETING; GENETIC HETEROGENEITY; HEALTH CARE ORGANIZATION; HISTOPATHOLOGY; HUMAN; MALIGNANT TRANSFORMATION; MEDICAL EDUCATION; METAPLASIA; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS BIOPSY; PANCREAS CANCER; PANCREAS DUCT; PANCREAS FUNCTION; PANCREAS INTRAEPITHELIAL CANCER; PANCREAS SURGERY; PANIC; PRIORITY JOURNAL; SURGICAL APPROACH; TRAINING;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; PANCREATIC NEOPLASMS;

EID: 31544439351     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3914     Document Type: Conference Paper

References (19)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Allison DC, Piantadosi S, Hruban RH, et al. DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J Surg Oncol 1998;67:151-9.
3. Kern S, Hruban R, Hollingsworth MA, et al. A white paper: the product of a pancreas cancer think tank. Cancer Res 2001;61:4923-32.
4. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004;2:606-21.
5. Kern SE. Molecular genetic alterations in ductal pancreatic adenocarcinomas. Med Clin North Am 2000;84:691-5, xi.
6. Martin NE, Brunner TB, Kiel KD, et al. A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin Cancer Res 2004;10:5447-54.
7. van der Heijden MS, Brody JR, Dezentje DA, et al. In vivo therapeutic responses contingent on Fanconi Anemia/BRCA2 status of the tumor. Clin Cancer Res 2005;11:7508-15.
8. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002;62:3789-93.
9. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 2005;66:95-106.
10. Kohl NE, Omer CA, Conner MW, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995;1:792-7.
11. Rangarajan A, Weinberg RA. Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer 2003;3:952-9.
12. Xing HR, Cordon-Cardo C, Deng X et al. Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer. Nat Med 2003;9:1266-8.
13. Miyamoto Y, Maitra A, Ghosh B, et al. Notch mediates TGF α-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003;3:565-76.
14. Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003;425:846-51.
15. Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003;425:851-6.
16. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95.
17. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92.
18. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437-50.
19. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005;129:504-11.